DNDi aims to deliver:

  • A new benznidazole monotherapy regimen.
  • A new benznidazole and fosravuconazole combination treatment regimen.
  • A new fexinidazole monotherapy regimen.
  • A new chemical entity to be tested in clinical trials for treatment of patients with chronic Chagas disease.

 

The current Chagas disease portfolio includes:

 Research

Discovery

Booster H2L
Chagas C205 series
Chagas H2L

Daiichi-Sankyo CH2L
Screening

 Translation

Translation

Biomarkers 
Fexinidazole
New Benznidazole Regimens +/- Fosravuconazole

 Implementation

Implementation

Benznidazole Paediatric Dosage Form

 

 

For more details on each project, see DNDi‘s Global Portfolio